Frazier Life Sciences Funds Detail Significant Investment in Mirum Pharmaceuticals Following Bluejay Acquisition

summarizeSummary

Frazier Life Sciences funds disclosed a significant $66.76 million investment in Mirum Pharmaceuticals through a private placement, acquiring shares and warrants at a discount following the Bluejay Therapeutics acquisition.

check_boxKey Events

• Significant Institutional Investment

  Frazier Life Sciences funds acquired approximately $66.76 million in Mirum Pharmaceuticals common stock and pre-funded warrants.

• Acquisition Financing Details

  The investment was part of a private placement on January 23, 2026, immediately following the completion of Mirum's acquisition of Bluejay Therapeutics, as previously disclosed on January 26, 2026.

• Discounted Purchase Price

  Shares and warrants were purchased at $68.48 per unit, representing a discount compared to the current stock price of $99.27.

• Updated Beneficial Ownership

  The filing updates the Frazier group's beneficial ownership, with Patrick J. Heron now holding 6.8% of the common stock.

auto_awesomeAnalysis

This Schedule 13D/A provides crucial details on the financing of Mirum Pharmaceuticals' recently completed acquisition of Bluejay Therapeutics. The Frazier Life Sciences group, a significant institutional investor, acquired approximately $66.76 million in common stock and pre-funded warrants on January 23, 2026, as part of a private placement. While these shares and warrants were purchased at a notable discount to the current market price, this substantial capital infusion from a prominent life sciences investor group signals confidence in Mirum's strategic direction and the value of the Bluejay acquisition. The filing also updates the Frazier group's overall beneficial ownership in Mirum.